Newsroom

LONDON--(BUSINESS WIRE)--  Re: ORBITA FUNDING 2023-1 PLC GBP 32,664,000.00 MATURING: 22-Oct-2030 ISIN: XS2699151457 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Apr-2026 TO 22-May-2026 HAS BEEN FIXED AT 6.54 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 22-May-2026 WILL AMOUNT TO: GBP 175,454.00 PER GBP 32,664,000.00 DENOMINATION  ...

LONDRA--(BUSINESS WIRE)--Experian, azienda globale specializzata in dati e tecnologia, e ServiceNow (NYSE: NOW), la piattaforma di controllo basata sull'AI dedicata alla trasformazione aziendale, oggi annuncia una nuova collaborazione mondiale pluriennale che sfrutta la potenza degli agenti AI autonomi su diverse piattaforme per aiutare le aziende a rendere più intelligenti e a velocizzare su larga scala i processi decisionali. Grazie a questa partnership, gli agenti AI autonomi potranno acquis...

LONDEN--(BUSINESS WIRE)--Experian, het internationale data- en technologiebedrijf, en ServiceNow (NYSE: NOW), de AI-controletoren om business opnieuw uit te vinden, onthulden vandaag een nieuw meerjarig globaal partnerschap dat de kracht van autonome AI agents in diverse platformen inzet im bedrijven te helpen sneller intelligentere beslissingen op schaal te nemen. Via dit partnerschap kunnen autonome AI agents het vermogen krijgen om sneller en consistenter te handelen, te beginnen met het aan...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by Natera’s Signatera™ CDx per...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in...

LONDON--(BUSINESS WIRE)--  Re: Lloyds Bank PLC USD 20,000,000.00 MATURING: 22-Nov-2028 ISIN: XS2723557620 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 23-Feb-2026 TO 22-May-2026 HAS BEEN FIXED AT 4.73 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 22-May-2026 WILL AMOUNT TO: USD 2,312.57 PER USD 200,000.00 DENOMINATION  ...

LONDRES--(BUSINESS WIRE)--Experian, la société mondiale spécialisée dans les données et les technologies, et ServiceNow (NYSE : NOW), la tour de contrôle IA pour la réinvention des entreprises, dévoilent aujourd’hui un nouveau partenariat mondial pluriannuel qui exploite la puissance des agents IA autonomes sur toutes les plateformes, aidant ainsi les entreprises à prendre des décisions plus rapides et plus intelligentes à grande échelle. Grâce à ce partenariat, les agents IA autonomes peuvent...

LONDON--(BUSINESS WIRE)--Experian, das globale Daten- und Technologieunternehmen, und ServiceNow (NYSE: NOW), der KI-Kontrollturm für die Neugestaltung von Unternehmen, geben heute eine neue globale, mehrjährige Partnerschaft bekannt, die die Leistungsfähigkeit autonomer KI-Agenten plattformübergreifend nutzt und Unternehmen dabei unterstützt, schnellere und intelligentere Entscheidungen in großem Maßstab zu treffen. Durch diese Partnerschaft erhalten autonome KI-Agenten die Fähigkeit, schnelle...

TORONTO--(BUSINESS WIRE)--Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX:S) provides a further update with respect to its decision of May 7, 2026 to suspend its direct participation in joint venture activities in Cuba in light of the Executive Order issued by the U.S. administration on May 1, 2026 expanding its sanctions against Cuba (the “Executive Order”). Sherritt’s interests in Cuba consist of: A 50/50 partnership with General Nickel Company S.A. (“GNC”) of Cuba (...

LONDON--(BUSINESS WIRE)--  Re: The Toronto-Dominion Bank (Covered Bonds) EUR 2,000,000,000.00 MATURING: 16-Feb-2027 ISIN: XS2782117118 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 19-May-2026 TO 17-Aug-2026 HAS BEEN FIXED AT 2.58 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 17-Aug-2026 WILL AMOUNT TO: EUR 12,910,000.00 PER EUR 2,000,000,000.00 DENOMINATION  ...